1. Introduction {#s0005}
===============

Mechanical strain caused by load-bearing informs the activity of osteoblasts which form new bone and osteoclasts which resorb surplus bone through mechanisms collectively referred to as functional adaptation. The opposing activities of these two cell types are normally balanced through coupling mechanisms involving direct and indirect signaling between members of their lineages ([@bb0335]). Key to this coupling is the secretion of receptor activator of nuclear factor κB ligand (RANKL) by osteoblastic lineage cells including terminally-differentiated osteocytes embedded within the bone matrix ([@bb0370]; [@bb0175]). RANKL binds its receptor RANK on osteoclast precursors and promotes their differentiation. Its activity is opposed by the decoy receptor osteoprotegerin (OPG) also secreted by osteoblasts and osteocytes ([@bb0380]; [@bb0175]). OPG expression is increased by activation of the potently-osteogenic canonical Wnt signaling pathway, which is required for osteoblast differentiation in part by promoting expression of the osteoblastic master regulator RUNX2 ([@bb0155]). Wnt signaling is antagonized by the osteocyte-specific secreted antagonist Sclerostin (SOST), which prevents excessive bone formation ([@bb0015]; [@bb0005]).

It is widely accepted that osteocyte-derived signals including RANKL and sclerostin fine-tune (re)modeling ([@bb0175]; [@bb0255]). The mechanisms integral to functional adaptation-induced (re)modeling appear to fail with age, leading to excessive resorption relative to formation and a deterioration of bone mass and architecture characteristic of osteoporosis ([@bb0240]; [@bb0130]). Elucidation of the cellular mechanisms involved has led to the clinical development of anti-RANKL antibody (Denosumab) and more recently and anti-sclerostin antibody (Romosozumab) ([@bb0055]). Expression of both SOST and RANKL is influenced by the transcription factor RUNX2 ([@bb0325]; [@bb0185]; [@bb0050]). Furthermore, the expression of both SOST and RANKL is down-regulated in osteoblastic lineage cells subjected to mechanical strain ([@bb0200]; [@bb0300]).

Whereas acute SOST down-regulation following strain permits increased bone formation, RANKL down-regulation is expected to reduce the drive for resorption. Therefore, down-regulation of both these osteocyte-secreted products may contribute to the ability of mechanical loading to uncouple bone formation from resorption ([@bb0100]; [@bb0110]). In the functionally-adapted skeleton, basal secretion of these mediators establishes the osteogenic context on which acute (re)modeling stimuli are superimposed. For example, although osteoblastic cells are themselves strain-responsive, the presence of sclerostin in their environment reduces their strain-related increase in proliferation ([@bb0115]; [@bb0125]). Following exposure to acute episodes of increased strains beyond the habitual, down-regulation of sclerostin is spatially related to new bone formation ([@bb0255]).

To study the mechanisms by which strain down-regulates SOST, we have previously reported an in vitro model in which exposure of human female Saos-2 osteosarcoma cells to physiological levels of substrate strain by four point bending results in SOST down-regulation in a peak strain magnitude-dependent manner over a time course consistent with that observed following mechanical loading of rodent bones in vivo ([@bb0110]; [@bb0115]). Saos-2 cells have been extensively used to study SOST and RANKL regulation because of their mature osteoblastic phenotype and physiological expression of these genes ([@bb0325]; [@bb0110]; [@bb0005]; [@bb0115]; [@bb0305]; [@bb0280]). In our model, SOST down-regulation following strain involves estrogen receptor signaling ([@bb0115]) and the prostaglandin signaling pathway through PGE2/EP4 ([@bb0110]). In the absence of strain, PGE2 acts as a coupling agent, decreasing SOST expression but increasing RANKL ([@bb0360]; [@bb0025]; [@bb0110]; [@bb0140]).

RANKL expression is also down-regulated in osteoblastic cells subjected to dynamic substrate strain ([@bb0310]; [@bb0315]; [@bb0095]; [@bb0290]; [@bb0205]), whereas simulated disuse in microgravity up-regulates RANKL ([@bb0320]). In vivo disuse is commonly achieved through rodent tail suspension, which has been reported to increase RANKL ([@bb0355]; [@bb0370]; [@bb0250]). Studies investigating the effects of increased loading have, to our knowledge, not yet clearly demonstrated the context and bone compartments in which strain down-regulates RANKL expression in vivo. One report found that, in rats, exercise and vibration training sufficient to prevent bone loss caused by glucocorticoid treatment also blunted the glucocorticoid-induced increase in osteocyte RANKL expression ([@bb0270]). In contrast, in vivo down-regulation of sclerostin by increased loading and its up-regulation following unloading have been extensively mapped ([@bb0300]; [@bb0025]; [@bb0135]; [@bb0005]; [@bb0240]).

The mechanisms by which mechanical stimulation reduces expression of both SOST and RANKL remain poorly delineated. Regulation of both these genes by the same transcription factor, RUNX2, led us to hypothesize that strain-mediated down-regulation of both SOST and RANKL involves RUNX2. In support of this hypothesis, mechanical stimulation activates RUNX2 in osteoblastic cells ([@bb0170]; [@bb0005]; [@bb0150]), leading to increased expression of the osteoblastic differentiation marker osteocalcin ([@bb0005]). However, whereas the role of RUNX2 in pre-osteoblasts has been extensively investigated, its actions in mature osteoblasts and osteocytes involved in functional adaptation to loading remain incompletely understood. Well-established functions of RUNX2 include its interactions with various epigenetic regulators such as histone deacetylase (HDAC) enzymes ([@bb0160]; [@bb0210]; [@bb0330]; [@bb0235]). HDACs turn off gene expression by removing acetylation groups recognized by acetyl reader enzymes including the bromodomain containing (BRD) proteins. Thus, we further hypothesized that RUNX2 could regulate SOST and RANKL expression by altering recruitment of epigenetic regulators to their promoters following strain. To investigate this we developed Saos-2 cells with stable transfection of short hairpin (sh)RUNX2 sequences or vector controls with which to study the effects of RUNX2 knockdown on SOST and RANKL regulation by mechanical strain.

2. Materials and methods {#s0010}
========================

2.1. Cells, reagents and lentiviral transfection {#s0015}
------------------------------------------------

Saos-2 cells were as previously described ([@bb0110]; [@bb0115]; [@bb0120]; [@bb0125]). Cells were maintained in phenol red-free DMEM containing 10% heat-inactivated FCS (PAA, Somerset, UK), 2 mM [l]{.smallcaps}-glutamine, 100 IU/ml penicillin and 100 IU/ml streptomycin (Invitrogen, Paisley, UK) (complete medium) in a 37 °C incubator at 5% CO~2~, 95% humidity as previously described ([@bb0110]; [@bb0115]). 5-Aza-2′-deoxycytidine (AzadC) was from Sigma-Aldrich (Dorset, UK) and dissolved in DMSO. For AzadC treatment Saos-2 cells were seeded in six-well plates at an initial density of 40,000 cells/cm^2^ in complete medium and allowed to settle overnight. Cells were then treated once with AzadC at a final concentration of 1 μM as previously reported to increase SOST expression by demethylating its promoter ([@bb0065]) and harvested three days later. Actinomycin D (ActD) was also from Sigma-Aldrich (Dorset, UK) dissolved in ethanol and used at a final concentration of 2 μM 1 h prior to strain. shRUNX2 sequences were as previously reported ([@bb0275]) cloned in pWTS1 vectors with enhanced green fluorescent protein (eGFP) for fluorescence-assisted cell sorting of shRUNX2- or pWTSL1 vector-transfected controls. shRUNX2 and pWTSL1 cells were treated identically throughout. For transfection, 20,000 Saos-2 cells were seeded in each well of 6-well dishes and allowed to adhere for 24 h in 5 ml of complete medium. A 100 μl lentiviral titer of shRUNX2 or pWSTL1 vector control was then added to each dish together with 5 μl Polybrene™ (4 μg/ml). The following day cells received a complete medium change to wash away any excess viral particles and 3 days later the cells were sub-cultured. Cells were further sub-cultured two more times in order to wash any residual virus and ensure stable transfection before eGFP FACS sorting. A 100 μl aliquot of sorted cells was re-sorted to confirm sorting accuracy and showed \>98% of sorted cells fell within the expected fluorescence window. The sorted cells were expanded and cryopreserved.

2.2. In vitro mechanical strain {#s0020}
-------------------------------

Mechanical strain was generated by four point bending as previously described ([@bb0110]; [@bb0115]; [@bb0240]). In brief, cells were seeded at an initial density of 40,000 cells/cm^2^ on custom-made plastic slides in 1 ml of complete medium, allowed to settle overnight, flooded with 5 ml/slide of complete medium and allowed to grow to over-confluence for 3 more days as this increases their SOST expression ([@bb0050]; [@bb0115]). Cells were then serum-deprived in 2% charcoal/dextran stripped FCS overnight before exposure to strain through a brief period of 600 cycles of four point bending of the strips with a peak strain of 3400 με on a Zwick/Roëll materials testing machine (Zwick Testing Machines Ltd., Leominster, UK) with strain rates on and off of \~24,000 με/s, dwell times on and off of 0.7 s and a frequency of 0.6 Hz.

2.3. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) {#s0025}
---------------------------------------------------------------------------

RT-qPCR was performed as previously described using our previously reported primers for SOST and the housekeeping gene β2-microglobulin ([@bb0110]; [@bb0115]). Human RUNX2 primers were: Forward 5′-TGCCTAGGCGCATTTCAGGTGC-3′, Reverse 5′-CCTGAGGTGACTGGCGGGGT-3′ producing a 151 bp amplicon. RANKL primers were from the Harvard Primer Bank ([@bb0340]) ID 197927084b1. Agarose gel visualization was as previously described ([@bb0110]). Primer sequences used for the panel of epigenetic regulators in our custom PCR array have been previously described ([@bb0090]). Each experiment involved 5 static and 5 strained slides pooled together to have enough RNA for down-stream processing.

2.4. Immunofluorescence and proliferation assay {#s0030}
-----------------------------------------------

Saos-2 Ki-67 immunofluorescence and proliferation assays were performed as previously described ([@bb0115]). Human RUNX2 antibodies and NorthernLights™-conjugated secondary antibodies were purchased from R&D Systems. For immunofluorescence, cells were permeabilized in 0.5% *v*/v Triton™ X-100 for 15 min, blocked for 1 h in 10% horse serum in PBS, and incubated with the appropriate primary antibody at a 1:200 dilution overnight. The next day, cells were washed 3 × 5 min in PBS with 0.5% v/v Triton™ X-100 before being incubated with a 1:200 dilution of the secondary antibody for 1 h at room temperature in the dark. Cells were then washed again 3 × 5 min in PBS and mounted in Fluoroshield DAPI (Sigma-Aldrich, Dorset, UK). Images were captured on a Leica DMRB microscope with an Olympus DP7.2 digital camera.

2.5. Alkaline phosphatase activity assays {#s0035}
-----------------------------------------

Alkaline phosphatase (ALP) activity assays corrected to total protein were performed as previously-described ([@bb0240]). Saos-2 cells were seeded at an initial density of 10,000 cells/cm^2^ in 24-well plates and cultured for 7 days in complete medium with half medium changes every 2 days. Cells were fixed in ice-cold methanol and alkaline phosphatase activity determined.

2.6. Chromatin immunoprecipitation (ChIP) {#s0040}
-----------------------------------------

RUNX2 and BRD2 ChIP assays were performed as previously described ([@bb0080]; [@bb0085]). Saos-2 cells were strained or kept as static controls and their DNA was cross-linked with 1% formaldehyde at room temperature for 15 min. Each experiment involved 5 static and 5 strained slides but all the slides needed to be pooled to have enough DNA for down-stream processing such that each n of 1 represents an independent experiment. ChIP primers were as follows: RUNX2 P1 Forward 5′-TCAGCATTTGTATTCTATCCAAATCC-3′, Reverse 5′-TGGCATCCAGAAGGATATAGCTTTT-3′; RANKL Promoter site A Forward 5′-CAAAGGTGTCCTCTGCGTCT-3′, Reverse 5′-CTCTGTCACTGAAGGGCCTC-3′; RANKL Promoter site B Forward 5′-CCACCCAAAGTGCTGGGATT-3′, Reverse 5′-ACCTGCAATTCTTTGGTGGC-3′.

2.7. Western blotting {#s0045}
---------------------

Western blotting was performed as previously described ([@bb0080]) on immuno-precipitated ChIP lysates from Saos-2 cells subjected to strain or kept as static controls. RUNX2 and IgG antibodies are from Santa Cruz, and the BRD2 antibody is from Cell Signaling. Blots were visualized with an ECL^+^ detection kit using a FluorChem M CCD camera (Cell Biosciences).

3. Results {#s0050}
==========

3.1. Mechanical strain down-regulates SOST and RANKL without altering RUNX2 expression {#s0055}
--------------------------------------------------------------------------------------

Exposure of Saos-2 cells to strain down-regulates SOST and RANKL, but not OPG expression 8 h later relative to static controls ([Fig. 1](#f0005){ref-type="fig"}A). Strain had no significant effect on RUNX2 expression ([Fig. 1](#f0005){ref-type="fig"}B). Despite their similar temporal regulation by strain, differences in SOST and RANKL regulation are observed when new RNA synthesis is inhibited with ActD pre-treatment 1 h before strain. ActD treatment had no effect on SOST basal expression relative to the housekeeping gene but prevented its down-regulation by strain ([Fig. 1](#f0005){ref-type="fig"}C), whereas the same treatment reduced relative RANKL expression to a level lower than strain and the superimposition of strain had no further effect ([Fig. 1](#f0005){ref-type="fig"}D). Together, our data demonstrate that mechanical strain suppresses expression of SOST and RANKL in Saos-2 cells.Fig. 1Mechanical strain alters gene expression in Saos-2 cells. Mechanical strain down-regulates SOST and RANKL (TNFSF11) expression, but does not alter OPG (TNFRSF11B) and RUNX2 expression in Saos-2 cells. RT-qPCR analysis of SOST, RANKL, OPG (A) and RUNX2 (B) subjected to strain for 8 h. RT-qPCR analysis of SOST (C) and RANKL (D) of cells pre-treated with 2 μM Actinomycin D or vehicle 1 h before exposure to strain for 8 h. Bars represent the mean ± SEM, *n* = 10--15. \* *p* \< .05, \*\* *p* \< .01, \*\*\* *p* \< .001 versus static controls.Fig. 1

3.2. Characterization of shRUNX2 cells {#s0060}
--------------------------------------

Transfection of Saos-2 cell with a lentiviral vector containing shRUNX2 and eGFP followed by FACS sorting permitted derivation of a stable cell line with greatly reduced RUNX2 expression relative to similarly transfected and sorted cells expressing the control pWST1 vector also expressing eGFP ([Fig. 2](#f0010){ref-type="fig"}A). RUNX2 knockdown did not alter basal proliferation as assessed with Ki-67 staining ([Fig. 2](#f0010){ref-type="fig"}B), but significantly reduced alkaline phosphatase (ALP) activity ([Fig. 2](#f0010){ref-type="fig"}C). RUNX2 knockdown did not alter basal RANKL expression ([Fig. 2](#f0010){ref-type="fig"}D), but it up-regulated SOST expression ([Fig. 2](#f0010){ref-type="fig"}E). These results demonstrate that RUNX2 knockdown increases SOST expression is Saos-2 cells.Fig. 2RUNX2 suppresses expression of SOST. Stable knockdown of RUNX2 in decreases alkaline phosphatase activity and increases SOST expression, but does not alter proliferation and RANKL levels in Saos-2 cells. RT-qPCR analysis of RUNX2 in vector control and shRUNX2 transfected cells (A). Percentage of Ki-67 positive cells (B) and alkaline phosphatase activity (ALP) (C) in vector control or shRUNX2 transfected cells. RT-qPCR analysis of RANKL (D) and SOST (E) in vector control or shRUNX2 transfected cells. Bars represent the mean ± SEM, n = 10--12 with the exception of B (*n* = 4). \*\* p \< .01, \*\*\* p \< .001 versus vector controls.Fig. 2

3.3. RUNX2 suppresses basal SOST expression and mediates RANKL down-regulation by strain {#s0065}
----------------------------------------------------------------------------------------

RUNX2 may modulate SOST expression in Saos-2 cells by either activating ([@bb0325]) or suppressing ([@bb0050]) its promoter activity. Under our conditions, when SOST expression was increased with the DNA methylation inhibitor AzadC as previously reported ([@bb0065]), cells lacking RUNX2 up-regulated SOST to a significantly lower extent than vector control cells ([Fig. 3](#f0015){ref-type="fig"}A). As neither RUNX2 knockdown nor AzadC had any significant effect on RANKL expression ([Fig. 3](#f0015){ref-type="fig"}B), we investigated the effect of the coupling agent PGE2 which is known to up-regulate RANKL. PGE2 up-regulated RANKL 8 h after treatment with no significant difference between shRUNX2 and vector control cells ([Fig. 3](#f0015){ref-type="fig"}C). Conversely, PGE2 down-regulated SOST expression in both shRUNX2 and vector control cells ([Fig. 3](#f0015){ref-type="fig"}D). Similarly, strain down-regulated SOST expression to a similar extent in vector control and shRUNX2 cells ([Fig. 3](#f0015){ref-type="fig"}E). However, strain was unable to down-regulate RANKL in cells lacking RUNX2 expression ([Fig. 3](#f0015){ref-type="fig"}F). Altogether, these results indicate that RUNX2 is involved in the strain-related down-regulation of RANKL but not SOST.Fig. 3Strain-mediated suppression of SOST proceeds independently of RUNX2. RUNX2 influences basal SOST expression but not regulation of SOST by strain, whereas strain-related RANKL down-regulation but not basal expression are influenced by RUNX2. Cells were treated with 1 μM AzadC for 3 days and assessed for SOST (A) and RANKL (B) expression by RT-qPCR analysis (n = 10). Vector control or shRUNX2 cells were treated with vehicle or 0.5 μM PGE2 and harvested 24 h later to assess for RANKL (C) and SOST (D) expression by RT-qPCR analysis (n = 10). Cells were subjected to strain and harvested 8 h later to assess for SOST (E) and RANKL (F) expression by RT-qPCR analysis (*n* = 15). Bars represent the mean ± SEM. \*\* p \< .01, \*\*\* p \< .001 versus static controls of the same cell type, ^\#\#\#^ p \< .001 versus AzadC-treated pWTS1 cells.Fig. 3

3.4. Strain reduces RUNX2 occupancy at the RANKL promoter {#s0070}
---------------------------------------------------------

To further delineate the RUNX2-dependant mechanisms by which strain down-regulates RANKL, we investigated RUNX2 binding to the RANKL promoter. An ACCAC putative RUNX2 binding site 201 bp from the isoform 1 start site had previously been suggested based on bioinformatic analysis of the RANKL promoter sequence in Saos-2 cells ([@bb0190]). This site will be referred to as Site A. Additionally, a second RUNX2 consensus binding sequence was identified 2494 bp from the start site, denoted Site B ([Fig. 4](#f0020){ref-type="fig"}A). ChIP analysis revealed RUNX2 occupancy of Site B but not Site A in confluent Saos-2 cells ([Fig. 4](#f0020){ref-type="fig"}B&C). The RUNX2 P1 promoter, known to be robustly occupied in Saos-2 cells ([@bb0060]), was used as a positive control in ChIP assays. Strain significantly reduced RUNX2 occupancy at the RANKL promoter Site B without altering occupancy of the RUNX2 P1 promoter ([Fig. 4](#f0020){ref-type="fig"}D). In summary, these results demonstrate that RUNX2 occupancy at the RANKL promoter is reduced by strain.Fig. 4RUNX2 occupancy of the RANKL promoter decreases following strain. Schematic representation of the RANKL promoter that encompasses two RUNX2 recognition motifs (5′-ACCACA) denoted Site A (201 bp from the isoform 1 start site) and Site B (2,494 bp from the start site) in Saos-2 cells (A). Half-arrows indicate PCR amplicons amplified. Agarose gel images of PCR-amplified ChIPs with either RUNX2 antibody or IgG negative control antibody, and 1% input PCR positive control, using primer pairs specific for Site A or Site B in the RANKL promoter (B). PCR quantification of ChIPs with RUNX2 or IgG antibodies using RANKL promoter or the RUNX2 P1 promoter primers (ND = not detected) (C). Percent change in RUNX2 occupancy of the RANKL Site B and RUNX2 P1 promoter 8 h following strain (D). Bars represent the mean ± SEM, *n* = 3 representing three independent experiments. \*\*p \< .01 for the effect of strain.Fig. 4

3.5. BRD2 is a strain and RUNX2 target gene {#s0075}
-------------------------------------------

RUNX2 is well known to interact with numerous epigenetic regulators which can influence promoter activity without directly altering RUNX2 expression ([@bb0160]; [@bb0210]; [@bb0330]). To investigate the potential implication of epigenetic regulators implicated with acetylation and methylation of histones (i.e., histone code writers, readers, and erasers), we used a custom-made PCR panel of 83 distinct genes of which 76 were robustly detected in all three repeat experiment using three housekeeping controls (HPRT, GAPDH and β2MG). Exposure to strain altered the expression of genes in our PCR panel following a normal distribution in both vector control of shRUNX2 cells ([Fig. 5](#f0025){ref-type="fig"}A). Expression analysis of epigenetic regulators ([Supplementary Table 1](#ec0005){ref-type="supplementary-material"}) revealed thirteen strain-responsive genes ([Fig. 5](#f0025){ref-type="fig"}B). The bromo-domain acetyl reader BRD2 was the gene most significantly down-regulated in the vector control cells, whereas its expression was non-significantly up-regulated following strain in the shRUNX2 cells. We have previously reported strain-related regulation of Brd2 in the tibiae of both young and old mice subjected to osteogenic axial loading in vivo ([@bb0130]). Unlike strain, knockdown of RUNX2 resulted in a skewed distribution towards down-regulation of the investigated epigenetic regulators ([Fig. 5](#f0025){ref-type="fig"}C). Of the examined epigenetic regulators ([Supplementary Table 2](#ec0010){ref-type="supplementary-material"}), all significantly regulated genes are down-regulated by RUNX2 knockdown ([Fig. 5](#f0025){ref-type="fig"}D). In addition to RUNX2 itself, the three genes most down-regulated by RUNX2 knockdown have all previously been reported to be direct RUNX2 target genes in Saos-2 cells ([@bb0060]). Altogether, these results establish that BRD2 expression is regulated by strain and RUNX2 activity.

3.6. BRD2 occupies the RANKL promoter but its occupancy decreases following strain {#s0080}
----------------------------------------------------------------------------------

It has been established that RUNX2 occupies the BRD2 promoter in Saos-2 cells ([@bb0060]). Interestingly, BRD2 was also shown to bind to the RUNX2 promoter ([@bb0215]). Thus, a feedback loop may exist between RUNX2 and the epigenetic reader BRD2. Similar to previous studies, ChIP analysis established BRD2 binding at the RUNX2 promoter ([Fig. 6](#f0030){ref-type="fig"}A). This assay also identified BRD2 occupancy at the RANKL promoter Site B. Western blotting of ChIP lysates demonstrated co-precipitation of RUNX2 and BRD2, suggesting they occupy the same protein complexes in both static and strained samples ([Fig. 6](#f0030){ref-type="fig"}B). Strain selectively reduced BRD2 occupancy of the RANKL promoter Site B without significantly altering its occupancy of the RUNX2 P1 promoter ([Fig. 6](#f0030){ref-type="fig"}C). These data confirm BRD2 occupancy at the RUNX2 promoter and strain-dependent occupancy at the RANKL promoter.Fig. 5BRD2 is a strain and RUNX2 responsive gene. shRUNX2 and vector control cells were subjected to strain and harvested 8 h later for quantification of candidate epigenetic regulators using custom RT-qPCR panels. Distribution of differences in the expression of candidate epigenetic regulators in vector control or shRUNX2 (A) and shRUNX2 cells versus vector control cells (B). *P* values indicated are Shapiro-Wilk\'s tests for normality, indicating that RUNX2 knockdown, but not strain, skewed the distribution of percentage changes in epigenetic candidate gene expression towards down-regulation (A and B). Epigenetic regulators significantly modulated by strain (C). When genes were significantly regulated in one but not the other cell type (control or shRUNX2), the percentage changes are shown but without asterisks over the non-significant bar (\* p \< .05, \*\* p \< .001 versus static controls of the same cell type). Epigenetic regulators differentially expressed between shRUNX2 and vector cells (p \< .05) (B). Arrows indicate genes previously reported to be RUNX2 targets in Saos-2 cells. Bars represent the mean ± SEM, n = 3 representing three independent experiments.Fig. 5Fig. 6BRD2 binding to the RANKL promoter is down-regulated by strain. Saos-2 were subjected to strain and harvested 8 h later for ChIP analysis using a BRD2 and IgG antibodies. Quantification of ChIP precipitates with primers for the RANKL promoter sites A and B or the RUNX2 P1 promoter (ND = not detected) (A). Western blot analysis of ChIP lysates or Input loading control (B). Percentage change in BRD2 occupancy of the RANKL Site B and RUNX2 P1 (C). Bars represent the mean ± SEM, n = 3 representing three independent experiments. \*p \< .05 versus static control.Fig. 6

4. Discussion {#s0085}
=============

The absence of bone formation in mice lacking RUNX2 demonstrates its critical role in osteoblast differentiation ([@bb0075]), yet its functions in mature osteoblast lineage cells are poorly understood. Here we demonstrate that RUNX2 suppresses basal SOST expression as its knockdown increases SOST expression, suggesting RUNX2 influences the osteogenic context through sclerostin. However, RUNX2 does not mediate the acute responses to strain which result in SOST down-regulation. Conversely, RUNX2 knockdown does not alter basal RANKL expression but prevents its down-regulation by strain. In investigating potential epigenetic mechanisms by which RUNX2 mediates strain-related RANKL down-regulation, we identified an epigenetic feedback loop between RUNX2 and BRD2, demonstrating that BRD2 also occupies the RANKL promoter and that its occupancy also decreases following strain.

Epigenetic regulation of SOST expression through DNA methylation has previously been reported ([@bb0065]; [@bb0295]; [@bb0220]; [@bb0345]). In the present study, the up-regulation of SOST expression induced by demethylation was sub-maximal in cells lacking maximal RUNX2 expression. This is consistent with the previous report that mutation of a RUNX2 binding site in a proximal fragment of the SOST promoter reduces promoter activity ([@bb0325]). Conversely, the finding that RUNX2 knockdown increases SOST expression is consistent with the report that transfecting additional RUNX2 into Saos-2 cells decreases SOST promoter activity ([@bb0050]). In our model of confluent Saos-2 cells expressing a mature osteoblastic phenotype ([@bb0050]; [@bb0115]; [@bb0280]), exposure to strain did not alter RUNX2 expression while strain has been reported to up-regulate RUNX2 in marrow stromal cells which then differentiate into osteoblasts ([@bb0195]; [@bb0105]; [@bb0185]). RUNX2 knockdown was sufficient to reduce ALP and increase basal SOST expression, but had no effect on SOST down-regulation by strain. SOST down-regulation requires new RNA synthesis, potentially including components of the prostaglandin ([@bb0110]), estrogen receptor ([@bb0115]), nitric oxide ([@bb0070]), and periostin ([@bb0030]) signaling pathways. The lack of change in basal SOST levels following 8 h of actinomycin D treatment suggest its RNA is relatively stable, at least as compared with RANKL expression which was significantly down-regulated by the same treatment. Thus, it is possible that the pathways involved in SOST down-regulation by strain may involve alterations in RNA stability, including microRNA mediated processes ([@bb0150]; [@bb0350]; [@bb0285]; [@bb0225]).

In contrast to its effects on SOST, knockdown of RUNX2 had no effect on basal RANKL expression. This is potentially consistent with the finding that mutating sites in the mouse RANKL promoter occupied by RUNX2 has no effect on its basal activity ([@bb0260]). RUNX2 knockdown did not alter RANKL up-regulation by PGE2. However, RUNX2 is required for strain to down-regulate RANKL in our model, suggesting that it is the presence of RUNX2 in mature osteoblastic cells which allows them to reduce the drive for resorption by down-regulating RANKL. In investigating the mechanisms by which RUNX2 mediates this, we first confirmed that RUNX2 binds the RANKL promoter in human Saos-2 cells. The RANKL promoter has been extensively studied and involves a large number of different regions and enhancer elements of varying importance in different cell types ([@bb0180]; [@bb0020]; [@bb0050]; [@bb0265]; [@bb0385]). Here we demonstrate that a proximal region of this promoter is responsive to strain because strain decreases its occupancy by RUNX2 and BRD2.

The action of RUNX2 on target promoters is entirely dependent on its recruitment of co-activators and co-repressors such as HDACs ([@bb0230]; [@bb0165]). We therefore used a custom PCR panel of epigenetic regulators to explore potential mechanisms by which RUNX2 occupancy of the RANKL promoter may decrease following strain. This panel reinforces the critical role RUNX2 plays in osteoblastic cell epigenetic networks, which is of recognized importance during osteoblast differentiation ([@bb0365]), as RUNX2 knockdown skewed the distribution of epigenetic gene expression towards down-regulation. shRUNX2 down-regulated the expression of several HDACs namely HDAC1, HDAC3 (which was further significantly down-regulated by strain in shRUNX2 but not vector control cells), HDAC4, HDAC5 and HDAC8. It has been established that HDACs bind to and modulate RUNX2 activity ([@bb0035]; [@bb0040]). Interestingly, our current studies suggest that RUNX2 may also govern expression of several HDACs in Saos-2 cells. The gene most significantly down-regulated by shRUNX2 was the bromodomain acetyl reader BRD2. This gene is also mechano-responsive in vivo ([@bb0130]).

Previously-reported ChIP-Seq experiments had identified RUNX2 occupancy of the BRD2 promoter in Saos-2 cells ([@bb0060]). It was also reported that BRD2 binds the RUNX2 promoter ([@bb0215]), as was also observed in this study. Furthermore we report that BRD2 and RUNX2 associate within complexes. Preliminary data suggests female transgenic mice with low BRD2 expression have lower RUNX2 expression than wild type controls and develop lower bone mass as adults ([@bb0045]). Thus, these findings delineate a novel feedback loop in which RUNX2 and BRD2 occupy each other\'s promoters, promote each other\'s expression, interact within protein complexes, and occupy the same sites on target promoters potentially relevant to bone (re)modeling.

BRD2 occupancy of the RANKL promoter was significantly reduced following exposure to strain. In contrast, strain did not alter BRD2 or RUNX2 binding to the P1 promoter of RUNX2 itself, which did not show significant changes in expression following strain. This suggests that additional, as yet unknown, regulatory steps specifically target RUNX2 and BRD2 on this promoter. The proposed role of BRD2 in RANKL regulation is potentially consistent with the recently-reported findings that pharmacological inhibition of BRD proteins is associated with reduced resorption ([@bb0215]; [@bb0245]; [@bb0010]; [@bb0145]). Pharmacological inhibitors of BRD proteins have gained attention in the treatment of various malignancies ([@bb0375]). Application of these pharmacological agents, as well as studies in BRD2 low-expression mice, may be able to extend the in vitro findings presented here in future experiments.

In conclusion, RUNX2 expression in osteoblastic cells expressing SOST and RANKL influences the osteogenic context in which strain acts by suppressing basal SOST levels and contributes to the acute down-regulation of RANKL following exposure to increased strain. These effects involve reduced binding of RUNX2 to the RANKL promoter following strain. RUNX2 knockdown alters the epigenetic landscape by predominantly down-regulating epigenetic regulators normally expressed in Saos-2 cells, including BRD2. BRD2 forms a feedback loop with RUNX2 and occupies the RANKL promoter, but its occupancy is also decreased following strain. Thus, RUNX2-targeting therapies may alter bone mass through their actions on SOST and RANKL in mature osteoblastic cells. BRD2 modulators already in clinical development are also expected to have effects on bone in part through interaction with loading-related RANKL regulation.

The following are the supplementary data related to this article.Supplementary Table 1Effect of strain on all epigenetic regulators included in the custom PCR panel. Vector control or shRUNX2 cells were subjected to strain or kept as static controls and harvested 8 h later. The lists are sorted according to the *p* value for the effect of strain in vector control cells. Red cells indicate *p* \< .05, green indicates 0.1 \> *p* \> .05. Data is presented as the average percentage change in expression (calculated as \[strain − static\] / static ∗ 100) and SEM, *n* = 3 representing three independent repeat experiments.Supplementary Table 1Supplementary Table 2Effect of RUNX2 knockdown on all epigenetic regulators included in the custom PCR panel. Static vector control or shRUNX2 cells were compared. The lists are sorted according to the p value associated with the percentage change in gene expression due to shRUNX2 (\[shRUNX2 − vector\]/vector ∗ 100). Red cells indicate p \< .05, green indicates 0.1 \> p \> .05. Data is presented as the average and SEM, n = 3 representing three independent repeat experiments.Supplementary Table 2
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